India, July 16 -- Alpha Tau Medical Ltd. (DRTS), an oncology therapeutics company, on Thursday announced the successful treatment of the first immunocompromised patient in the ADMIRE trial evaluating intratumoral Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma.
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is an investigational therapy designed to enable intratumoral treatment of solid tumors by placing sources directly into the tumor, where they release short-lived therapeutic particles that disperse locally to destroy the tumor.
Immunosuppression is a common risk factor in patients of cutaneous squamous cell carcinoma (cSCC), resulting from organ transplantation, hematological malignancies like chronic lymph...